AlphaStocks

AZN vs CRVL

ASTRAZENECA PLC vs CORVEL CORP — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

CRVL

CORVEL CORP

3.8

Weak

$54.15

AZN vs CRVL: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while CORVEL CORP (CRVL) scores 3.8/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, CORVEL CORP trades at 29.6x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNCRVL
Scores & Fundamentals
Composite Score8.4/103.8/10
RatingStrong BuyWeak
Price$200.99$54.15
P/E Ratio30.429.6
ROE21.9%10.7%
Market Cap$312B$3B
Fair Value$192.63$41.26
Dividend Yield1.6%
Sector Rank#3 of 1127#888 of 1127
Model Verdicts
PiotroskiStrongStrong
BuffettStrongLimited Data
GrahamCautionCaution
LynchNeutralLimited Data
GreenblattNeutralLimited Data
View full AZNanalysis →View full CRVLanalysis →
Compare any two stocks →

AZN vs CRVL: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and CORVEL CORP (CRVL) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to CRVL's 3.8/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer